Investigating how clozapine affects a specific group of patients with schizophrenia
1/5 - Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11093521
This study is looking at how clozapine, a medication for schizophrenia, can be better matched to help people with a specific type of the condition, using their unique brain characteristics to improve their treatment and minimize side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11093521 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how clozapine, an effective antipsychotic medication, can be tailored to benefit patients with a specific subtype of schizophrenia identified through biomarkers. The study utilizes a large database of individuals with psychosis to categorize them into distinct biotypes based on their neurobiological characteristics. By examining the response of these biotypes to clozapine, the research aims to improve treatment outcomes and reduce side effects associated with this medication. Patients will be monitored for changes in symptoms and cognitive function as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who exhibit low cognition and high symptom severity, specifically those classified as Biotype 1.
Not a fit: Patients who do not have schizophrenia or those who do not fit into the identified biotypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with schizophrenia, particularly those who may not respond well to standard therapies.
How similar studies have performed: Previous research has shown promise in using biomarker-defined subgroups to tailor treatments for psychiatric conditions, indicating a potential for success in this novel approach.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TAMMINGA, CAROL A — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: TAMMINGA, CAROL A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.